Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Cash from Financing Activities (2016 - 2026)

Nutex Health (NUTX) has disclosed Cash from Financing Activities for 14 consecutive years, with -$49.5 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 627.38% year-over-year to -$49.5 million; the TTM value through Mar 2026 reached -$140.7 million, down 1133.33%, while the annual FY2025 figure was -$97.9 million, 9077.91% down from the prior year.
  • Cash from Financing Activities hit -$49.5 million in Q1 2026 for Nutex Health, down from -$45.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.7 million in Q1 2024 and bottomed at -$49.5 million in Q1 2026.
  • Average Cash from Financing Activities over 5 years is -$11.6 million, with a median of -$4.3 million recorded in 2023.
  • Year-over-year, Cash from Financing Activities tumbled 7144.95% in 2022 and then soared 137.74% in 2023.
  • Nutex Health's Cash from Financing Activities stood at -$14.8 million in 2022, then surged by 73.47% to -$3.9 million in 2023, then increased by 23.72% to -$3.0 million in 2024, then tumbled by 1433.52% to -$45.8 million in 2025, then dropped by 8.21% to -$49.5 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$49.5 million, -$45.8 million, and -$29.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.